Erasca reports Q3 EPS (11c), consensus (10c)

“Our RAS-targeting franchise continues to advance rapidly, with multiple important clinical milestones approaching,” said Jonathan Lim, Erasca’s (ERAS) chairman, CEO, and co-founder. “A U.S. patent was issued that covers the composition of matter for our potential best-in-class pan-RAS molecular glue ERAS-0015, the first of several patents we anticipate may be issued, which would strengthen the intellectual property surrounding our differentiated RAS portfolio. We also reinforced our scientific leadership with the promotion of Robert Shoemaker, Ph.D., to chief scientific officer. As a core member of Erasca’s founding team, Robert has been instrumental in shaping our research strategy since company inception.”